Orchid Pharma Limited reported earnings results for the fourth quarter and full year ended March 31, 2023. For the fourth quarter, the company reported sales was INR 2,099.01 million compared to INR 1,781.32 million a year ago. Revenue was INR 2,116.3 million compared to INR 1,798.79 million a year ago. Net income was INR 591.4 million compared to net loss of INR 65.86 million a year ago. Basic earnings per share from continuing operations was INR 16.15 compared to basic loss per share from continuing operations of INR 1.14 a year ago. Diluted earnings per share from continuing operations was INR 16.15 compared to diluted loss per share from continuing operations of INR 1.14 a year ago. Basic earnings per share was INR 14.49 compared to basic loss per share of INR 1.61 a year ago. Diluted earnings per share was INR 14.49 compared to diluted loss per share of INR 1.61 a year ago.
For the full year, sales was INR 6,658.98 million compared to INR 5,595.57 million a year ago. Revenue was INR 6,853.29 million compared to INR 5,685.6 million a year ago. Net income was INR 463.18 million compared to net loss of INR 19.51 million a year ago. Basic earnings per share from continuing operations was INR 13.01 compared to basic loss per share from continuing operations of INR 14.8 a year ago. Diluted earnings per share from continuing operations was INR 13.01 compared to diluted loss per share from continuing operations of INR 14.8 a year ago. Basic earnings per share was INR 11.35 compared to basic loss per share of INR 0.48 a year ago. Diluted earnings per share was INR 11.35 compared to diluted loss per share of INR 0.48 a year ago.